Did it seem like research and development was slowing down in the hair growth treatment sector? Allergan doesn't think so. Today, November 14, 2019, it was announced that Allergan has invested $25 million in the company Exicure to development treatments for hair loss. Exicure is a biotechnology company based in Skokie, Illinois developing numerous therapeutics for inflammatory diseases with its proprietary spherical nucleic acid or SNA technology. Under the agreement with Allergan, Exicure will be leading not one, but two research programs in alopecia. According to today's press release, Exicure will be eligible to receive development milestone payments up to $97.5 million for each program.

Source: https://www.folliclethought.com/allergan-invests-25-million-into-new-hair-loss-drugs/